HUM
48
6
SYK
64
-4
COP
56
2
INTU
51
2
A
36
2
IVZ
46
3
AMP
69
-3
JNPR
46
3
CAG
30
4
VFC
47
-5
CVX
46
5
NWSA
62
2
DHR
35
3
AES
39
-4
MUR
43
3
LB
34
8
PRU
57
-3
AMGN
44
5
MA
55
-7
MRO
55
3
HUM
48
6
SYK
64
-4
COP
56
2
INTU
51
2
A
36
2
IVZ
46
3
AMP
69
-3
JNPR
46
3
CAG
30
4
VFC
47
-5
CVX
46
5
NWSA
62
2
DHR
35
3
AES
39
-4
MUR
43
3
LB
34
8
PRU
57
-3
AMGN
44
5
MA
55
-7
MRO
55
3
Financhill
Back

Axsome Therapeutics 10K Form

Buy
61

AXSM
Axsome Therapeutics

Last Price:
98.18
Seasonality Move:
43.77%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AXSM News And Ratings

See the #1 stock for the next 7 days that we like better than AXSM

AXSM Financial Statistics

Sales & Book Value

Annual Sales: $270.6M
Cash Flow: $-18.72M
Price / Cash Flow: 0
Annual Sales: $1.92
Price / Book: 48.23

Profitability

EPS (TTM): -6.53000
Net Income (TTM): $-310.96M
Gross Margin: $244.54M
Return on Equity: -194.28%
Return on Assets: -54.66%

Axsome Therapeutics Earnings Forecast

Key Axsome Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 4 years for AXSM is 90.37%.
  • The Selling, General & Administrative Expenses for AXSM have been equal to 119.41% of Gross Profit Margin.
  • The Research & Development expenses have been 36.20% of Revenue.
  • The Interest Expense is -2.70% of Operating Income.
  • The Net Earning history of AXSM is -88.41% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 2 years.

Axsome Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: AXSM
CUSIP: 05464T
Website: axsome.com

Debt

Debt-to-Equity Ratio: 1.94
Current Ratio: 2.44
Quick Ratio: 2.3

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AXSM Technical Analysis vs Fundamental Analysis

Buy
61
Axsome Therapeutics (AXSM) is a Buy

Is Axsome Therapeutics a Buy or a Sell?